With rising cancer prevalence and greater adoption of minimally invasive and image-guided diagnostic procedures, the biopsy devices market in Japan is projected to expand at a compound annual growth rate (CAGR) of 3% through 2036, forecasts GlobalData, a leading data and analytics company.

GlobalData’s report, “Biopsy Devices Market Size by Segments, Share, Regulatory, Reimbursement, Interventions and Forecast to 2036,” reveals that in 2024, Japan accounted for 25% of the Asia–Pacific (APAC) biopsy devices market. The market expansion is propelled by advancements in high-performance medical technologies and sustained investment in healthcare infrastructure, with local manufacturers driving much of the momentum.

Shamreen Parween, Medical Devices Analyst at GlobalData, comments: “The increasing complexity of conditions such as cancer and growing demand for personalized therapies have increased the need for techniques that enable earlier and more accurate detection. Biopsy testing offers higher diagnostic accuracy, and shorter patient recovery times that reduce trauma and improve outcomes.”

Olympus recently introduced SecureFlex, a single‑use fine‑needle biopsy device, in Europe and Japan. The product is scheduled for commercial release in those markets in autumn 2025, with broader global distribution to follow pending regulatory approvals and product registrations. Designed for use with ultrasound endoscopes, the needle features a dual‑beveled raptor tip that promotes smooth penetration and effective tissue capture, yielding larger, intact specimens and improving the reliability of pathological assessment to meet rising demand for advanced minimally invasive diagnostic solutions.

Parween concludes: “In Japan, the growing biopsy devices market highlights the need for diagnostic tools that offer high precision and enable early disease detection. This trend is also leading to increased R&D investments from both international and domestic manufacturers.”